canertinib has been researched along with Carcinoma, Epidermoid in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Aunoble, B; Bourhis, J; Rolhion, C; Tortochaux, J | 1 |
Ako, E; Hirakawa, K; Hori, T; Kubo, N; Ohira, M; Sawada, T; Yamashita, Y; Yamazaki, M | 1 |
de Bock, C; Denny, WA; Ferguson, LR; Gieseg, MA | 1 |
1 review(s) available for canertinib and Carcinoma, Epidermoid
Article | Year |
---|---|
[Targeting of epidermal growth factor receptor and applications in ORL cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Morpholines; Neoplasm Proteins; Otorhinolaryngologic Neoplasms; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Quinazolines | 2003 |
2 other study(ies) available for canertinib and Carcinoma, Epidermoid
Article | Year |
---|---|
The pan-erbB tyrosine kinase inhibitor CI-1033 inhibits human esophageal cancer cells in vitro and in vivo.
Topics: Animals; Carcinoma, Squamous Cell; Cell Proliferation; ErbB Receptors; Esophageal Neoplasms; Female; Humans; Mice; Mice, Inbred BALB C; Mitogen-Activated Protein Kinase Kinases; Morpholines; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Receptor, ErbB-2; Xenograft Model Antitumor Assays | 2007 |
Evidence for epidermal growth factor receptor-enhanced chemosensitivity in combinations of cisplatin and the new irreversible tyrosine kinase inhibitor CI-1033.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Division; Cells, Cultured; Cisplatin; DNA Adducts; DNA Repair; Drug Administration Schedule; Drug Synergism; Enzyme Inhibitors; ErbB Receptors; Fibroblasts; Humans; Luciferases; Mice; Morpholines; Tumor Cells, Cultured | 2001 |